SUDA Ltd. and Amherst Pharmaceuticals have entered a cross-licence and collaboration agreement to develop and commercialise SUDA's oral spray of ondansetron (SUD-002) for the treatment of nausea and vomiting induced by chemotherapy or radiotherapy, and Amherst's oral spray of zolpidem tartrate (Zolpimist)for insomnia. Under the terms of the agreement, SUDA is granting Amherst an exclusive licence to manufacture, develop and commercialise SUD-002 in the Americas and South Africa. SUDA receives an exclusive licence to manufacture, develop and commercialise Zolpimist in all territories excluding the Americas and South Africa.

Both parties have the right to sub-license in their respective territories. SUDA is entitled to a 6% to 12% share of income from Amherst's commercialisation of SUD-002 in the Americas and South Africa. Similarly, Amherst will receive a 6% to 12% share of income from SUDA's commercialisation of Zolpimist in SUDA's territories.